People who have unfairly been denied the pleasure of enjoying the
company of cats due to allergies have taken great joy
This week after the announcement of a possible vaccine for this problem. With the
vaccine, which is given to cats, is supposed to be less likely to
These cats cause allergies. But although the news promises, it will not be possible
Acquire the vaccine until at least 2022.
The Swiss company Hypocat is developing the vaccine, which is its medicine
main experimental and that also has the same name. Hypocat published the
Results of a study on the vaccine in April. However, for some
reason, the Internet has begun to talk excitedly about this news another
The study, published in the newspaper Journal of Allergy and Clinical
Immunology, describes a very intelligent strategy to combat
Allergies that cause cats.
Unlike other types of immunotherapy, this vaccine does not attempt
desensitize the immune system of people allergic to cats.
Instead, try to train the immune system of cats so that
attack a specific protein, or an allergen, that these animals produce from
naturally called Fed d 1. You are supposed to achieve this by setting a
genetically modified version of the protein to a particle, similar to a
virus, derived from a plant virus (since it is only a particle, not
should be able to cause disease).
About 90 percent of people with a cat allergy
produce antibodies to Fel d 1. Therefore, if Hypocat is successful, your vaccine
basically it would turn cats into hypoallergenic beings by
reduction of the amount of Fel d 1 that they produce and that eventually reaches
Our noses and mouths.
In the study, the vaccine apparently did just this. Doses were administered to more than 50 young cats by an injection in their hind legs and several experiments were performed. In the last experiment, cats received three doses over nine weeks. Some cats received a booster shot six months later.
It was reported that all cats developed a sustained immune response. In addition, the booster vaccine managed to keep its antibody levels high. The cats' blood antibodies also seemed to neutralize Fel d 1 in the laboratory, and the cats produced less Fel 1 d in their saliva and tears. When the samples of the cats were mixed with blood from human patients who had an allergy to cats, there was no great reaction.
Above all, animal lovers will be happy to learn that the vaccine did not appear to cause serious or long-term effects in cats. One reason for this could be that Fel d 1 does not have a critical function in cats, as far as we know. Some cats naturally have low levels of Fel d 1 and have no health problems. In addition, the vaccine does not eliminate the protein completely.
The news is exciting, but it is also important to note that
Data are preclinical trials.
Hypocat CEO Gary Jennings told Gizmodo that the company
is talking with the agencies responsible for the approval of medications in
United States and the European Union, and that has already begun to conduct tests
clinical and make preparations for mass production.
But although the vaccine gets very good results in clinical trials,
You will still have to wait for years to reach the market. The company too
is working on a similar vaccine for dogs, called Hypodog,
which is not as developed as the cat vaccine.
"If everything goes according to plan, we hope to reach the market in 2022," he said